Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-26.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -53.92% |
| Return on Assets (Trailing 12 Months) | -48.58% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.85 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.85 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 30.98M |
| Free Float | 29.58M |
| Market Capitalization | $65.67M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 1.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 21.09% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |